BCR and B-cell chronic lymphocytic leukemia: PI3K inhibitors—among which the δ subunit inhibitor idelalisib has been the first and most widely tested, also at a clinical level—are another class of drugs that induce the apoptosis of CLL cells through the dual inhibition of the BCR signaling and of the chemokine receptor-dependent activation of Akt, that are key mechanisms in promoting microenvironment-induced survival of leukemic cells2,3.